8-K: Vivani Medical Appoints Seasoned Biotech Finance Executive Anthony Baldor as New Chief Financial Officer

Vivani Medical, Inc. announced the appointment of Anthony Baldor, a finance veteran with over two decades of experience in the biotechnology sector, as its new Chief Financial Officer, succeeding Brigid Makes who is retiring.

Summary

• Vivani Medical, Inc. (NASDAQ: VANI) has appointed Anthony Baldor as its new Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective June 15, 2025.
• Mr. Baldor succeeds Brigid Makes, who resigned from her roles effective June 15, 2025, to focus on board appointments and personal projects; her departure was not due to any disagreement with the Company.
• Anthony Baldor, age 43, brings over 20 years of financial management experience in the biotechnology sector, with a proven track record in fundraising, business development, and corporate strategy.
• His prior roles include Chief Financial Officer at Diakonos Oncology Corp. (January 2024 December 2024), where he led Series Seed and Series A financings, and Vice President of Corporate Strategy and Development at 4D Molecular Therapeutics, Inc. (July 2019 June 2023), where he was instrumental in Series C financing, IPO, and key partnership activities.
• Mr. Baldor's compensation package includes an initial base salary of $450,000 per year, a cash bonus program, and an initial option award to purchase 600,000 shares of common stock, vesting over four years.
• Brigid Makes will continue to serve in an advisory capacity during the transition period.
• Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants using its proprietary NanoPortal platform, with lead programs for chronic weight management (NPM-115, NPM-139) and type 2 diabetes (NPM-119).

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the appointment of a highly experienced and qualified Chief Financial Officer with a strong background in biotech financing and corporate strategy, coupled with the amicable departure of the previous CFO. This strengthens the management team at a pivotal time for the company's pipeline advancement.

Positives

• The appointment of Anthony Baldor brings extensive financial management experience (over 20 years) in the biotechnology sector, including a strong background in fundraising (Series Seed, Series A, Series C financings, IPO) and corporate strategy.
• The outgoing CFO, Brigid Makes, is retiring and her departure was explicitly stated not to be based on any disagreement with the Company, indicating a smooth transition.
• Mr. Baldor's experience aligns well with a clinical-stage company like Vivani, which is advancing its pipeline and scaling operations, suggesting a strategic hire for future growth and potential capital needs.
• The company's CEO, Adam Mendelsohn, expressed excitement about Baldor joining the leadership team at a 'pivotal time' for the company, highlighting the strategic importance of this appointment.

Negatives

• No specific negative points were identified in the document regarding the management change or company operations.

Risks

• Risks that the proposed spin-off of Cortigent, Inc. will not be completed in a timely manner or at all.
• Risks of failure to satisfy any conditions required for the Cortigent spin-off.
• Risks that the spin-off may not qualify for non-recognition of gain or loss for U.S. Federal Income Tax purposes.
• Risks related to obtaining necessary approvals from the U.S. Securities and Exchange Commission (SEC) and Nasdaq for the spin-off.
• Uncertainty regarding whether the anticipated benefits of the Cortigent spin-off can be achieved.
• Risks of unexpected costs or delays associated with company operations and strategic initiatives.
• Risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies, and objectives.
• Risks related to the development and commercialization of Vivani's products, including NPM-115, NPM-139, and NPM-119.
• Potential delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations, and guidelines.
• Potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities.
• Risks related to the initiation, enrollment, and conduct of Vivani's planned clinical trials and the results therefrom.
• Vivani's history of losses and its ability to access additional capital or otherwise fund its business.
• Market conditions and the ability of Cortigent to complete its spin-off.
• Cortigent's history of losses and its ability to access additional capital or otherwise fund its business and advance its product candidates and pre-clinical programs.

Future Outlook

Vivani Medical aims to advance its pipeline and scale its operations, with specific plans for the development of NPM-115, NPM-139, and NPM-119. The company also anticipates the completion of the LIBERATE-1TM trial and reporting of its results, alongside plans for the proposed spin-off of its wholly-owned subsidiary, Cortigent, Inc.

Management Comments

• "Anthony's deep expertise in financial strategy will be instrumental as Vivani advances its pipeline and scales its operations. We are excited to welcome him to the leadership team at this pivotal time for the Company." Adam Mendelsohn, PhD, Chief Executive Officer of Vivani Medical.
• "On behalf of the Board and the entire Vivani team, I thank Brigid for her outstanding leadership and dedication. Her expertise and vision have been invaluable to our growth and success. This includes helping guide our company through a transformative period, including the successful completion of the merger of Nano Precision Medical and Second Sight Medical Products, and the advancement of our clinical and commercial strategy." Adam Mendelsohn, PhD, Chief Executive Officer of Vivani Medical.

Industry Context

Vivani Medical operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on developing long-acting drug implants for chronic conditions like weight management and type 2 diabetes. The company's NanoPortal platform aims to address medication non-adherence, a significant issue contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. alone. While the GLP-1 landscape is crowded with over 50 new molecular entities in clinical development, Vivani believes its differentiated miniature, ultra long-acting implants offer a unique therapeutic option for patients, prescribers, and payers.

Comparison to Industry Standards

• Anthony Baldor's background includes leadership roles at other biotechnology companies such as Diakonos Oncology Corp. and 4D Molecular Therapeutics, Inc., demonstrating experience within the biopharmaceutical industry.
• His prior experience in leading Series Seed, Series A, Series C financings, and an initial public offering (IPO) at previous companies aligns with the typical financial milestones and capital needs of clinical-stage biotech firms.
• His tenure at Jefferies Group, LLC in Equity Research provides an understanding of capital markets and investor perspectives, which is a valuable asset for a public biopharmaceutical company.

Management Changes

Corporate Governance

Related Party Transactions

• The document explicitly states that there are no arrangements or understandings between Mr. Baldor and any other persons pursuant to which he was appointed, no family relationships between Mr. Baldor and any other director or executive officer, and Mr. Baldor has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO with a strong background in fundraising and corporate strategy could instill confidence and potentially improve future financial outcomes and strategic direction.
• Employees: A stable and experienced leadership team, particularly in finance, can contribute to overall company stability and strategic clarity.
• Customers/Patients: Continued advancement of the pipeline under strong financial leadership could lead to the development and commercialization of new therapeutic options for chronic conditions.

Next Steps

• The Company plans to file the full text of Anthony Baldor's offer letter agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
• Vivani Medical will continue to advance its pipeline and scale its operations.
• The Company expects the completion of the LIBERATE-1TM trial and the reporting of its trial results.
• Continued development of Vivani's product candidates, including NPM-115, NPM-139, and NPM-119.
• Further plans regarding Cortigent, Inc., a wholly owned subsidiary, and its proposed spin-off.

Key Dates

Recommendation

Keywords

Vivani Medical, Anthony Baldor, Chief Financial Officer, CFO appointment, biopharmaceutical, drug implants, NanoPortal platform, GLP-1, weight management, type 2 diabetes, SEC filing, 8-K, corporate governance, executive change, clinical-stage, financing, capital raise